Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Sarah L. Gulliford, Emma Hall, Allison Steigler, James W. Denham, Jason Dowling, Michael G Jameson, D. Roach, David Joseph, Peter B. Greer, Angel Kennedy, David P. Dearnaley, Marco Marcello, Annette Haworth, Lois Holloway, Matthew R. Sydes, Martin A. Ebert
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:1304-1318
Purpose Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to subclinical disease is associ
Autor:
Alison Parry-Jones, F.C. Ingleby, Mahesh K. B. Parmar, Rosalind A. Eeles, Claire Amos, Zsofia Kote-Jarai, Noel W. Clarke, Nafisah B. Atako, Matthew R. Sydes, Andrea Loehr, Chris Wanstall, Clare Gilson, Duncan C. Gilbert, Alex Hoyle, Simon Chowdhury, Christopher D. Brawley, Marina Parry, Nicholas D. James, Malcolm David Mason, Melissa Gannon, Adnan Ali, Ruth E Langley, Gerhardt Attard, Andrew Simmons, Zafar Malik
Publikováno v:
JCO Precision Oncology. :882-897
PURPOSEThe STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tum
Autor:
Claire L Vale, Sylvie Chabaud, Matthew R. Sydes, Andrew Kneebone, Mahesh K. B. Parmar, Paul Sargos, Carol Fraser-Browne, Chris Brown, David Fisher, Adrian Cook, Silvia Forcat, Chris Parker, Maria Pearse, Pierre Richaud, Meryem Brihoum, Christopher D. Brawley, Igor Latorzeff, Jayne F. Tierney
Publikováno v:
The Lancet. 396:1422-1431
Summary Background It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic re
Autor:
Noel W. Clarke, Claire Amos, Hassan Douis, Nicholas D. James, Gerhardt Attard, Malcolm David Mason, Mahesh K. B. Parmar, Adrian Cook, Chris Parker, Alex Hoyle, J. Calvert, Christopher D. Brawley, Adnan Ali, Matthew R. Sydes
Publikováno v:
Ali, A, Hoyle, A, Parker, C C, Brawley, C D, Cook, A, Amos, C, Calvert, J, Douis, H, Mason, M D, Attard, G, Parmar, M K B, Sydes, M R, James, N D & Clarke, N 2020, ' The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer : An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison” ', European Urology Oncology . https://doi.org/10.1016/j.euo.2020.05.003
European Urology Oncology
European Urology Oncology
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone me
Autor:
Malcolm David Mason, Martin J. Russell, Daniel M. Aebersold, Mahesh K. B. Parmar, Clare Gilson, David Matheson, Simon Chowdhury, Robert Jones, Silke Gillessen, William Cross, Hassan Douis, Adnan Ali, Alex Hoyle, Gerhardt Attard, A.W.S. Ritchie, Christopher D. Brawley, Johann S. de Bono, Chris Parker, David P. Dearnaley, Fiona C. Ingleby, Noel W. Clarke, Adrian Cook, Matthew R. Sydes, Nicholas D. James, Robin Millman
Publikováno v:
European Urology. 76:719-728
Background Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naive prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains u
Autor:
Val Bryant, Katie Gillies, Karen Matvienko-Sikar, Matthew R. Sydes, Nikki Rousseau, Elaine Toomey, Catherine Houghton, Linda Biesty, Megan McCarthy, Carrol Gamble, Julia Wade, Maura Dowling
Publikováno v:
HRB Open Research
Houghton, C, McCarthy, M, Gillies, K, Rousseau, N, Wade, J, Gamble, C, Toomey, E, Matvienko-Sikar, K, Sydes, M, Dowling, M, Bryant, V & Biesty, L 2021, ' A study protocol of qualitative data sharing practices in clinical trials in the UK and Ireland : towards the production of good practice guidance ', HRB Open Research, vol. 4 . https://doi.org/10.12688/hrbopenres.13269.2
Houghton, C, McCarthy, M, Gillies, K, Rousseau, N, Wade, J, Gamble, C, Toomey, E, Matvienko-Sikar, K, Sydes, M, Dowling, M, Bryant, V & Biesty, L 2021, ' A study protocol of qualitative data sharing practices in clinical trials in the UK and Ireland : towards the production of good practice guidance ', HRB Open Research, vol. 4 . https://doi.org/10.12688/hrbopenres.13269.2
Background: Data sharing enables researchers to conduct novel research with previously collected data sets, thus maximising scientific findings and cost effectiveness, and reducing research waste. The value of sharing anonymised data from clinical tr
Autor:
Tim Maughan, Joshua Hordern, Louise Brown, Richard Kaplan, Liz Morrell, Parmar Mkb., Matthew R. Sydes, Claire Amos
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-6 (2019)
Trials
Trials
Background Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials unit at University College Lo
Publikováno v:
European Urology Focus. 5:125-133
Context Androgen deprivation therapy (ADT) is the standard of care for men with metastatic hormone-sensitive prostate cancer (HSPC) and a potential treatment option in those with prostate-specific antigen relapse after local therapy. Based on promisi
Autor:
Malcolm David Mason, Robin Millman, Alison Birtle, Duncan McLaren, David Matheson, Stephanie Gibbs, John Graham, Prabir Chakraborti, Mahesh K. B. Parmar, Joanna Gale, Matthew S. Simms, Melissa Gannon, John Wagstaff, Anna T.H. Tran, J. Martin Russell, Robert Hughes, Joe M. O'Sullivan, Santhanam Sundar, Omi Parikh, Beth Woods, Mymoona Alzouebi, Audrey Cook, Richard Cathomas, Angus Robinson, Eleftherios Sideris, Robert Jones, Robert W. Laing, Susannah Brock, Clive Peedell, Narayanan Srihari, Chris Parker, Shaun Tolan, Gerhardt Attard, Nicholas D. James, Matthew R. Sydes, Alastair W. S. Ritchie, Andrew Protheroe, Mark Sculpher, William Cross, David Tsang, George N. Thalmann, Rajaguru Srinivasan, John Staffurth, David P. Dearnaley
Publikováno v:
Woods, B S, Sideris, E, Sydes, M R, Gannon, M R, Parmar, M K B, Alzouebi, M, Attard, G, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P R, Cook, A, Cross, W R, Dearnaley, D P, Gale, J, Gibbs, S, Graham, J D, Hughes, R, Jones, R J, Laing, R, Mason, M D, Matheson, D, McLaren, D B, Millman, R, O'Sullivan, J M, Parikh, O, Parker, C C, Peedell, C, Protheroe, A, Ritchie, A W S, Robinson, A, Russell, J M, Simms, M S, Srihari, N N, Srinivasan, R, Staffurth, J N, Sundar, S, Thalmann, G N, Tolan, S, Tran, A T H, Tsang, D, Wagstaff, J, James, N D & Sculpher, M J 2018, ' Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness ', European urology oncology, vol. 1, no. 6, pp. 449-458 . https://doi.org/10.1016/j.euo.2018.06.004
European Urology Oncology
European Urology Oncology
Background Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs fai
Autor:
Adrian Cook, Alex Hoyle, Nicholas D. James, Christopher D. Brawley, Matthew R. Sydes, Noel W. Clarke, Silke Gillessen, J. Calvert, Gerhardt Attard, Adnan Ali, David P. Dearnaley, Malcolm David Mason, Aine M Haran, Hassan Douis, Claire Amos, Mahesh K. B. Parmar, Chris Parker
Publikováno v:
Ali, A, Hoyle, A, Haran, A, Brawley, C D, Cook, A, Amos, C, Calvert, J, Douis, H, Mason, M D, Dearnaley, D P, Attard, G, Gillessen Sommer, S, Parmar, M, Parker, C, Sydes, M R, James, N D & Clarke, N 2021, ' Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2020.7857
Importance Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d29b8ec036335ac4a530ff10ac5d7b
https://research.manchester.ac.uk/en/publications/2900b072-8b82-4343-ac8b-2d78e8b14ad4
https://research.manchester.ac.uk/en/publications/2900b072-8b82-4343-ac8b-2d78e8b14ad4